English
Back
Download
Log in to access Online Inquiry
Back to the Top
avatar
Moomoo AI Mar 9, 2024 20:33

Despite Editas Medicine's stock price surge, its P/S ratio r...

Despite Editas Medicine's stock price surge, its P/S ratio remains modest due to inferior revenue forecasts. Without revenue improvement, the P/S ratio will continue to limit the share price.
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more
Translate
Report
30K Views
Comment
Sign in to post a comment
    avatar
    Moomoo AI
    Moomoo AI Official Account
    Your AI assistant for discovering investment opportunities.
    4719
    Followers
    0
    Following
    10K
    Visitors
    Follow
    Heat List
    US
    SymbolMini ChartLatest Price
    NVDA
    NVIDIA
    -- 135.910
    TSLA
    Tesla
    -- 394.740
    AMD
    Advanced Micro Devices
    -- 116.040
    RGTI
    Rigetti Computing
    -- 8.9300
    PLTR
    Palantir
    -- 67.260
    News
    U.S. Bank Stocks Kick Off Earnings Season! Will Trump 2.0's Regulatory Easing Propel Stock Prices to New Heights?
    15:26
    Nvidia Shares Move Lower After Report Co's Top Customers Face Delays From Glitchy AI Chip Racks, Last Down 4% Premarket
    40 mins ago
    NVIDIA Statement on the Biden Administration's Misguided 'AI Diffusion' Rule
    19:57
    Today's Pre-Market Movers and Top Ratings | ANF, LULU, ITCI and More
    21:45
    Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal
    21:39
    Discussing
    Trump 2.0 countdown: What's the next big opportunity in the markets?
    🎙️️ Discussion: 1. Could Trump's cryptocurrency policies potentially benefit the crypto market? 2. Might his tariff policies have a positiv Show More
    Ask a strategist - Trump's first day
    View More